We read the information written in DNA and RNA — and rewrite it. Our work spans CRISPR-based gene therapy, genetics and epigenetics, screening-based studies of disease mechanism, and open web tools for the community.
Sequences, large structural variants, and base modifications — and screening-based approaches that connect them to disease mechanism.
Web-based tools that make new methods usable by anyone — from BE-Designer and PE-Analyzer to CRISPRLungo.
Base and prime editing therapeutics, validated for efficiency and safety — for genetic and non-genetic disease alike.
We started in September 2025 and are building the founding group. Graduate students (M.S. / Ph.D.), undergraduate interns, and postdocs are all welcome — from wet-lab, computational, or mixed backgrounds.
Email the PI